EPO and anemia (phenotype): Through recombinant DNA technology, recombinant EPO (rhEPO) is now one of the most widely used drugs to treat anemia in patients with chronic kidney disease (CKD), acquired immune deficiency syndrome, multiple myeloma, myelodysplastic syndromes, and chemotherapy-induced anemia.